Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors

• Published in: British journal of cancer Vol. 129; no. 12; pp. 1893 - 1902
• Main Authors: Thompson, Jeffrey C., Scholes, Dylan G., Carpenter, Erica L., Aggarwal, Charu
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 07.12.2023; Nature Publishing Group
• Subjects: 631/67/1612/1350; 631/67/1857; Biomedical and Life Sciences; Biomedicine; Cancer Research; Clinical medicine; Drug Resistance; Epidemiology; Genotyping; Lung cancer; Malignancy; Medicine; Molecular Medicine; Mutation; Non-small cell lung carcinoma; Oncology; Patients; Plasma; Response rates; Review Article; Small cell lung carcinoma; Solid tumors; Tumor cells; Tumors
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/s41416-023-02445-1

The therapeutic landscape for patients with advanced malignancies has changed dramatically over the last twenty years. The growing number of targeted therapies and immunotherapeutic options available have improved response rates and survival for a subset of patients, however determining which patients will experience clinical benefit from these therapies in order to avoid potential toxicities and reduce healthcare costs remains a clinical challenge. Cell-free circulating tumor DNA (ctDNA) is shed by tumor cells into systemic circulation and is already an integral part of routine clinical practice for the non-invasive tumor genotyping in advanced non-small cell lung cancer as well as other malignancies. The short half-life of ctDNA offers a unique opportunity to utilize early on-treatment changes in ctDNA for real-time assessment of therapeutic response and outcome, termed molecular response . Here, we provide a summary and review of the use of molecular response for the prediction of outcomes in patients with advanced cancer, including the current state of science, its application in clinic, and next steps for the development of this predictive tool.